#ESMO18 Coverage
News, ESMO Congress TV, Photo Reportage, Daily Reporter, Meeting Resources and much more
Our open access, online journal, ESMO Open is now listed in Pubmed Central, only 10-months after launch. Learn more about the journal!
Read the Editor's choice articles
ESMO members are invited to attend the 2018 GA, 22 October in Munich, Germany, during the ESMO Congress. Join us and approve the new ESMO Bylaws.
ESMO’s flagship scientific journal, Annals of Oncology, publishes editorials, reviews, original articles and letters related to oncology
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Dr. Peter Schmid reports on key results from ESMO 2018 Congress: LBA1_PR: IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in treatment-naive, locally advanced or metastatic triple-negative breast cancer.
21 Oct 2018
There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to...
20 Oct 2018
Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-)
20 Oct 2018
Immunotherapy improves survival in some patients with metastatic triple negative breast cancer
20 Oct 2018
Treatment with the cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients...
20 Oct 2018
Longer survival and higher response seen with nivolumab and ipilimumab combination
20 Oct 2018
Avelumab shows promising clinical benefit and safety
Munich, Germany
19 Oct
- 23 Oct
2018
Amsterdam, Netherlands
08 Nov
- 11 Nov
2018
Lisbon, Portugal
09 Nov
- 10 Nov
2018
Lugano, Switzerland
16 Nov
- 17 Nov
2018
Singapore
21 Nov
- 22 Nov
2018
Singapore
23 Nov
- 25 Nov
2018
